A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program

[1]  H. Rugo,et al.  Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer , 2023, Breast.

[2]  H. Rugo,et al.  Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer , 2022, npj Breast Cancer.

[3]  M. Montelongo,et al.  251P Real-world clinical outcomes of palbociclib plus endocrine therapy (ET) in hormone receptor–positive advanced breast cancer: Results from the POLARIS trial , 2022, Annals of Oncology.

[4]  Kieran Hart,et al.  Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study. , 2022, Cancer treatment and research communications.

[5]  Kieran Hart,et al.  Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study. , 2021, Future oncology.

[6]  K. Wilner,et al.  Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men , 2021, Clinical pharmacology and therapeutics.

[7]  R. Pazdur,et al.  Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. , 2021, The Lancet. Oncology.

[8]  S. Loi,et al.  ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  G. Hortobagyi,et al.  LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) , 2021, Annals of Oncology.

[10]  G. Bertelli,et al.  240P A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program , 2021, Annals of Oncology.

[11]  A. Schneeweiss,et al.  Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Shahid Ahmed,et al.  Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer , 2021, Current oncology.

[13]  Xiaojia Wang,et al.  Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study , 2021, Annals of translational medicine.

[14]  H. Rugo,et al.  Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice , 2021, Breast Cancer Research.

[15]  A. Bernardo,et al.  Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study , 2021, Therapeutic advances in medical oncology.

[16]  P. Cottu,et al.  Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer , 2020, Breast.

[17]  N. Hu,et al.  Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices. , 2020, Future oncology.

[18]  J. Byun,et al.  Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[19]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[20]  F. Petracci,et al.  RENATA study—Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer—real-world use , 2020, Ecancermedicalscience.

[21]  C. Pacilio,et al.  Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis , 2020, International Journal of Molecular Sciences.

[22]  G. Basaran,et al.  Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial , 2020, Balkan Medical Journal.

[23]  F. Montemurro,et al.  Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials , 2019, Cancers.

[24]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer , 2019, Clinical Cancer Research.

[25]  Jianjun He,et al.  The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer , 2019, BMC Cancer.

[26]  D. Mitra,et al.  Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study , 2019, Journal of global oncology.

[27]  R. Bose,et al.  Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[28]  D. Mitra,et al.  Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. , 2019, Breast.

[29]  E. Sawyer,et al.  Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience , 2019, Breast Cancer Research and Treatment.

[30]  M. Agterof,et al.  Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy , 2019, Breast cancer : basic and clinical research.

[31]  A. Ring,et al.  Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper , 2018, Therapeutic advances in medical oncology.

[32]  B. Feinberg,et al.  Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval , 2018, Breast Cancer Research.

[33]  K. Gelmon,et al.  Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  G. Hortobagyi,et al.  Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial , 2017, Breast Cancer Research and Treatment.

[35]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[36]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[37]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[38]  S. Duffy,et al.  Treatment and survival in breast cancer in the Eastern Region of England. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Cynthia X. Ma,et al.  Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT , 2009 .